2Morrow, Inc., a leader in offering evidence-based, digital health platforms, announces a $1.5M investment led by Seattle area life science investor WRF Capital. The funding will be used to support growth of 2Morrow’s current platform and expansion into medical grade, digital therapeutic solutions for chronic conditions.
Human behaviors drive over half of today’s healthcare costs, and the mental and emotional toll of living with a chronic condition can result in increased instances of depression, anxiety and substance use disorders. The CDC recommends including behavioral modification or therapy in most care plans, however, these treatments are seldom offered due to lack of training, access, stigma or cost. Digitally addressing health through behavioral science, 2Morrow’s expanded platform will make it easier for healthcare providers to prescribe and distribute behavioral programs alongside other treatment options.
“We look forward to partnering with the 2Morrow team as it builds on its experience in the behavior modification arena to make high quality, evidence-based digital therapeutics available,” says Loretta Little, Managing Director, WRF Capital. “Physicians and patients need user-friendly, effective digital solutions that complement currently prescribed treatments.”
While prescribed digital treatments have recently gained traction in healthcare settings, 2Morrow has been a pioneer and leader in the field since 2011. Having collaborated with some of the leading experts in Acceptance & Commitment Therapy research and practice, 2Morrow has participated in multiple clinical trials to inform their evidence-based programs. Most recently, Fred Hutchinson Cancer Research Center completed a Phase 3 clinical trial validating 2Morrow’s exclusively licensed digital health approach to behavior modification specifically for smoking cessation.
“2Morrow is well positioned to take what we have learned about changing behaviors over the years to accelerate the efforts to create medical grade digital therapeutics,” says Jo Masterson, CEO, 2Morrow. “We are excited to have the experienced life science investors at WRF Capital lead this round. In addition, we appreciate the support of the Alliance of Angels, Frontier Angels, Zelkova, and the individual investors who believe in our vision.”